Last €0.58 EUR
Change Today +0.025 / 4.47%
Volume 4.0K
R3X On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 11:08 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (R3X) Snapshot

Open
€0.53
Previous Close
€0.56
Day High
€0.58
Day Low
€0.53
52 Week High
01/10/14 - €1.30
52 Week Low
08/30/13 - €0.23
Market Cap
104.0M
Average Volume 10 Days
10.8K
EPS TTM
--
Shares Outstanding
178.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (R3X)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (R3X) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (R3X) Details

Rexahn Pharmaceuticals, Inc., a development stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt, which has completed a Phase IIa clinical trials for the treatment of pancreatic cancer; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action that is in Phase Ib clinical trials for the treatment of solid tumors; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase, which is in Phase I clinical trials for the treatment of solid tumors. The company’s pre-clinical product pipeline consists of RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, an anticancer nano-polymer drug. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries, Ltd.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Ohio State University; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.

16 Employees
Last Reported Date: 03/21/14

rexahn pharmaceuticals inc (R3X) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (R3X) Key Developments

Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors

Rexahn Pharmaceuticals, Inc. announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin(TM) (RX-5902) in cancer patients with solid tumors. Enrollment into four dose groups has been completed (25, 50, 100 and 150 mg) and no drug related adverse events have been reported. The fifth dose group (225 mg) is ongoing. The maximum tolerated dose of Supinoxin has not yet been achieved. Pharmacokinetic analysis has shown that Supinoxin displays dose-proportional exposure and an estimated oral bioavailability of 51%. The Phase I trial of Supinoxin, which was initiated in August 2013, is a dose-escalation study designed to evaluate the safety, tolerability, dose-limiting toxicities and MTD in patients with solid cancer tumors that have previously failed treatment with approved therapies and shown progression of disease. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. This trial is being conducted in three clinical oncology centers in the United States. Each patient has the ability to continue on the drug up to six cycles of treatment (a dosing cycle is defined as 3 weeks of drug treatment followed by 1 week off) if no disease progression is seen. Patients are assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy to assess tumor progression. The trial is using an accelerated dose-escalation design: one patient is treated per dose cycle until a grade 2 related adverse event occurs then three patients will be treated per dose cycle. The decision to escalate dose is made by the data monitoring safety board (DMSB) after completion of one cycle of treatment based on safety and tolerability. Patients have the possibility to receive up to 6 cycles of treatment if the disease does not progress. Tumor biopsy samples are taken to assess the biomarker phospho-P68.

Rexahn Pharmaceuticals, Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

Rexahn Pharmaceuticals, Inc. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

Rexahn Pharmaceuticals, Inc. Approves Amendment to Amended and Restated Certificate of Incorporation

Rexahn Pharmaceuticals, Inc. approved an amendment to the company's amended and restated certificate of incorporation to effect a reverse stock split of the company's common stock at a ratio within the range of 1:2 to 1:6, as determined by the Board of Directors, together with a corresponding proportional reduction in the number of authorized shares of the company's capital stock.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
R3X:GR €0.58 EUR +0.025

R3X Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for R3X.
View Industry Companies
 

Industry Analysis

R3X

Industry Average

Valuation R3X Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.